<DOC>
	<DOCNO>NCT02307617</DOCNO>
	<brief_summary>The purpose study learn measure brain chemical brain scan call Magnetic Resonance Imaging Spectroscopy ( MRI/MRS ) brain activity ( know cortical excitability inhibition ) collect Transcranial Magnetic Stimulation ( TMS ) different adolescent depression different stage treatment . Researchers conduct study learn brain work adolescent depression without depression ( healthy control ) . This important may identify biological marker ( measure bad illness ) depression could one day use identify depressed adolescent would benefit certain treatment ( medication example ) monitor well treatment work .</brief_summary>
	<brief_title>Glutamate Probes Adolescent Depression</brief_title>
	<detailed_description>This cross-sectional longitudinal neurophysiology research study 200 adolescent subject vary stage major depressive disorder ( MDD ) . The aim study design gain understanding ( 1 ) role glutamate neurophysiology pharmacologic treatment child adolescent MDD ; ( 2 ) role gamma-aminobutyric acid ( GABA ) neurophysiology pharmacologic treatment child adolescent MDD ; ( 3 ) trajectory glutamatergic GABAergic function human development MDD . Glutamate concentration anterior cingulate cortex ( ACC ) leave dorsolateral prefrontal ( L-DLPFC ) cortex evaluate use proton magnetic resonance spectroscopy ( MRS ) 3 Tesla ( 3T ) . Glutamatergic cortical excitability measure ( motor threshold intracortical facilitation paradigm ) , GABAergic cortical inhibitory measure ( cortical silent period intracortical inhibition paradigm ) study use single paired-pulse transcranial magnetic stimulation ( TMS ) paradigm .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>1 . Adolescents age 13 21 , male female . 2 . Subjects MDD ( Groups 2 , 3 &amp; 4 ) : Must diagnosis Major Depressive Disorder ( MDD ) Single episode recurrent ; moderate severe . The MDD diagnosis base Kiddie Schedule Affective Disorders Schizophrenia School Aged Children Past Lifetime ( KSADSPL ) . This semistructured psychiatric interview administer psychiatrist , Ph.D. level psychologist , equivalent professional extensive clinical experience . Must Childhood Depression Rating ScaleRevised ( CDRSR ) score ≥ 40 Must Clinical Global Impression Severity ( CGIS ) Scale ≥ 4 3 . Group 1 : ( Healthy Controls ; 50 Subjects ) : Healthy volunteer 1321 year age current lifetime mental health diagnosis current lifetime psychotropic medication treatment . 4 . Group 2 : ( 50 subject ) : Subjects moderate severe MDD SSRI clinically indicate . If initiating SSRI treatment , medication must start ± 7 day baseline visit Subjects parent group 2 eligible return 68 week follow visit include mood assessment evaluation . Subjects adherent clinically prescribed medication eligible second MRI/MRS scan TMS measure within 7 day second visit . Subjects choose initiate treatment SSRI baseline visit Subjects discontinue change medication baseline eligible followup visit Group 3 : ( 50 subject ) : Subjects moderate severe MDD respond treatment SSRI . • Response define 1 ( much ) 2 ( much ) improve CGIImprovement Scale . This current acceptable standard child adolescent psychopharmacological research . Group 4 : ( 50 subject ) : Subjects moderate severe MDD respond treatment SSRI define CGI scale score . 5 . Subject parent guardian ( age 18 ) must capable provide informed consent 6 . Subjects least 1 parent must fluent English . • Subjects 18 year age old require Englishspeaking parent 4.2 Exclusion Criteria For Subjects : 1 . Contraindications MRI/MRS , determine MRI safety screen MRI safety code . 2 . Subjects judge Principal Investigator imminent risk selfharm suicide indicate interview CSSRS . 3 . Pregnancy suspect pregnancy female . 4 . Metal head ( except mouth* ) , implanted medication pump , cardiac pacemaker ( *subjects brace exclude MRI/MRS portion study ) 5 . Prior brain surgery . 6 . Risk increase intracranial pressure brain tumor . 7 . Any unstable medical condition . 4.2.1 Exclusion Criteria Healthy Control Group : 1 . Current past mental health diagnosis subject first degree relative subject . 2 . Current past mental health medication . 4.2.2 Exclusion Criteria MDD Groups : 1 . Primary Axis I II disorder MDD . 2 . Unprovoked seizure history , seizure disorder , history febrile seizure , first degree relative epilepsy 3 . Taking medication ( ) low seizure threshold 4 . Any significant finding TMS adult safety screen ( TASS ) . 4.2.3 Exclusion Criteria Group 2 : 1 . Subject start SSRI medication 7 day prior baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>healthy control</keyword>
	<keyword>selective serotonin reuptake inhibitor</keyword>
	<keyword>SSRI</keyword>
	<keyword>depression</keyword>
	<keyword>transcranial magnetic stimulation</keyword>
	<keyword>TMS</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>MRS</keyword>
	<keyword>adolescent</keyword>
	<keyword>mild MDD</keyword>
	<keyword>mild depression</keyword>
	<keyword>cortical excitability</keyword>
	<keyword>cortical inhibition</keyword>
	<keyword>cortical silent period</keyword>
	<keyword>motor threshold</keyword>
	<keyword>intracortical facilitation</keyword>
	<keyword>intracortical inhibition</keyword>
	<keyword>motor cortex</keyword>
	<keyword>dorsolateral prefrontal cortex</keyword>
	<keyword>DLPFC</keyword>
	<keyword>thumb twitch</keyword>
	<keyword>gamma aminobutyric acid</keyword>
	<keyword>GABA</keyword>
	<keyword>glutamate</keyword>
	<keyword>single pulse</keyword>
	<keyword>pair pulse</keyword>
</DOC>